SCD and metabolic dysfunction-associated steatohepatitis: Since SCD1 is mainly expressed in lipogenic tissues such as liver and adipose tissues (39), the possibility to consider SCD1 as a potential therapeutic target for the treatment of metabolic disorders including obesity and NASH has been investigated in previous studies (40).